C12N 2795/10171
Demonstrated in vivo effect
C12N2795/10171 (Demonstrated in vivo effect) appears on 19 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 19
- Published applications
- 24
- Assignees
- 13
- Inventors
- 35
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 4 |
| 2018 | 2 | 0 |
| 2019 | 2 | 3 |
| 2020 | 0 | 1 |
| 2021 | 3 | 4 |
| 2022 | 0 | 0 |
| 2023 | 2 | 1 |
| 2024 | 4 | 7 |
| 2025 | 3 | 1 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bacteriophage compositions for treating Pseudomonas infection7 Apr 2026US 12,594,312 B2Armata Pharmaceuticals, Inc.
- Bacteriophage compositions and methods for treatment of bacterial infections17 Mar 2026US 12,576,119 B2Baylor College of Medicine
- Bacteriophage therapy25 Nov 2025US 12,478,652 B2Ferring B. V.
- Antibacterial composition and uses thereof22 Apr 2025US 12,280,080 B2Erytech Pharma
- Bacteriophage compositions and methods for treatment of bacterial infections15 Apr 2025US 12,274,723 B2Baylor College of Medicine
- Bacteriophage compositions and methods for treatment of bacterial infections11 Sep 2025US 2025/0281555 A1Baylor College of Medicine
- Phage therapy of e coli infections7 Nov 2024US 2024/0366694 A1Erytech Pharma
- Bacteriophage therapy17 Oct 2024US 2024/0342230 A1Ferring B. V.
- Bacteriophage compositions and methods for treatment of bacterial infections10 Oct 2024US 2024/0335489 A1Baylor College of Medicine
- Bacteriophage compositions for treating pseudomonas infection11 Jul 2024US 2024/0226205 A1Armata Pharmaceuticals, Inc.
Most cited
By later US patents
- Phage therapy of pseudomonas infections6US 10,077,431 B2Pherecydes Pharma · 2018
- Clostridium perfringens bacteriophage Clo-PEP-1 and use thereof for inhibiting proliferation of clostridium perfringens5US 10,028,984 B2Intron Biotechnology, Inc. · 2018
- Method for prevention and treatment of Escherichia coli infections using a bacteriophage with broad antibacterial spectrum against Escherichia coli4US 9,433,653 B2Intron Biotechnology, Inc. · 2016
- Phage therapy of Pseudomonas infections3US 10,260,051 B2Pherecydes Pharma · 2019
- Enterohemorrhagic E. coli bacteriophage Esc-CHP-1 and use thereof for inhibiting proliferation of enterohemorrhagic E. coli3US 10,265,353 B2Intron Biotechnology, Inc. · 2019